These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26686256)

  • 41. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
    Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
    Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.
    van de Donk NW; van der Holt B; Minnema MC; Vellenga E; Croockewit S; Kersten MJ; von dem Borne PA; Ypma P; Schaafsma R; de Weerdt O; Klein SK; Delforge M; Levin MD; Bos GM; Jie KG; Sinnige H; Coenen JL; de Waal EG; Zweegman S; Sonneveld P; Lokhorst HM
    Lancet Haematol; 2018 Oct; 5(10):e479-e492. PubMed ID: 30290905
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intranasal topical estrogen in the management of epistaxis in hereditary hemorrhagic telangiectasia.
    Minami K; Haji T
    Acta Otolaryngol; 2016; 136(5):528-31. PubMed ID: 26808464
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study.
    Geisthoff UW; Seyfert UT; Kübler M; Bieg B; Plinkert PK; König J
    Thromb Res; 2014 Sep; 134(3):565-71. PubMed ID: 25005464
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term experience with intranasal bevacizumab therapy.
    Steineger J; Osnes T; Heimdal K; Dheyauldeen S
    Laryngoscope; 2018 Oct; 128(10):2237-2244. PubMed ID: 29469958
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells.
    Fernandez-L A; Garrido-Martin EM; Sanz-Rodriguez F; Ramirez JR; Morales-Angulo C; Zarrabeitia R; Perez-Molino A; Bernabéu C; Botella LM
    Thromb Haemost; 2007 Feb; 97(2):254-62. PubMed ID: 17264955
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bevacizumab: an option for refractory epistaxis in hereditary haemorrhagic telangiectasia.
    Amann A; Steiner N; Gunsilius E
    Wien Klin Wochenschr; 2015 Aug; 127(15-16):631-4. PubMed ID: 25986996
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.
    Dupuis-Girod S; Ginon I; Saurin JC; Marion D; Guillot E; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Lorcerie B; Rivière S; Corre R; Giraud S; Bailly S; Paintaud G; Ternant D; Valette PJ; Plauchu H; Faure F
    JAMA; 2012 Mar; 307(9):948-55. PubMed ID: 22396517
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hereditary HaemorrhagicTelangiectasia--A Rare Cause of Severe Anaemia.
    Deshpande P; Bhat S; Karmarkar A
    J Assoc Physicians India; 2014 Dec; 62(12):48-51. PubMed ID: 26259423
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical Practice Guideline: Nosebleed (Epistaxis).
    Tunkel DE; Anne S; Payne SC; Ishman SL; Rosenfeld RM; Abramson PJ; Alikhaani JD; Benoit MM; Bercovitz RS; Brown MD; Chernobilsky B; Feldstein DA; Hackell JM; Holbrook EH; Holdsworth SM; Lin KW; Lind MM; Poetker DM; Riley CA; Schneider JS; Seidman MD; Vadlamudi V; Valdez TA; Nnacheta LC; Monjur TM
    Otolaryngol Head Neck Surg; 2020 Jan; 162(1_suppl):S1-S38. PubMed ID: 31910111
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia.
    Rohrmeier C; Sachs HG; Kuehnel TS
    Eur Arch Otorhinolaryngol; 2012 Feb; 269(2):531-6. PubMed ID: 21805356
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Effects of bevacizumab on familial epistaxis caused by hereditary hemorrhagic telangiectasia].
    Zhang J; Wang XS; Wang HT
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2021 May; 56(5):436-441. PubMed ID: 34010995
    [No Abstract]   [Full Text] [Related]  

  • 53. First experiences with an individual nasal olive in patients with hereditary haemorrhagic telangiectasia (HHT).
    Al Kadah B; Papaspyrou G; Schneider M; Schick B
    Eur Arch Otorhinolaryngol; 2015 Jan; 272(1):117-22. PubMed ID: 24854232
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Thalidomide Effects in Patients with Hereditary Hemorrhagic Telangiectasia During Therapeutic Treatment and in Fli-EGFP Transgenic Zebrafish Model.
    Peng HL; Yi YF; Zhou SK; Xie SS; Zhang GS
    Chin Med J (Engl); 2015 Nov; 128(22):3050-4. PubMed ID: 26608985
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Use of Beta-Blockers in Hereditary Hemorrhagic Telangiectasia-Related Epistaxis: A Systematic Review.
    Albarki H; Rimmer J
    Am J Rhinol Allergy; 2022 Nov; 36(6):890-896. PubMed ID: 35929049
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of epistaxis in hereditary hemorrhagic telangiectasia patients by argon plasma coagulation with local anesthesia.
    Pagella F; Semino L; Olivieri C; Corno S; Dore R; Draghi F; Lanzarini L; Vespro V; Buscarini E; Danesino C
    Am J Rhinol; 2006; 20(4):421-5. PubMed ID: 16955772
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of epistaxis in hereditary haemorrhagic telangiectasia (HHT) patients using pulsed dye laser and the effect of withholding treatment during the COVID pandemic.
    Jiang Y; Dennis SC; Brewin MP
    Lasers Med Sci; 2022 Oct; 37(8):3147-3153. PubMed ID: 35635649
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Taking thalidomide out of rehab.
    Akhurst RJ
    Nat Med; 2010 Apr; 16(4):370-2. PubMed ID: 20376039
    [No Abstract]   [Full Text] [Related]  

  • 59. Anaesthetic management for caesarean section in a patient with hereditary haemorrhagic telangiectasia and severe epistaxis during pregnancy.
    Fogang D C; Martin G; Boehlen F; Savoldelli GL
    BMJ Case Rep; 2023 Oct; 16(10):. PubMed ID: 37788916
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.